Jae-Gook Shin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5182381/publications.pdf

Version: 2024-02-01

149 papers	4,948 citations	101543 36 h-index	110387 64 g-index
151 all docs	151 docs citations	151 times ranked	5779 citing authors

#	Article	IF	Citations
1	Ongoing Initiatives in Bringing the Preemptive Panelâ€"Based Pharmacogenetic Testing to Clinical Decisions in Vietnam. IFMBE Proceedings, 2022, , 553-567.	0.3	0
2	The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population. BMC Medical Genomics, 2022, 15, 3.	1.5	2
3	Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. International Journal of Infectious Diseases, 2022, 117, 8-14.	3.3	12
4	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19. Translational and Clinical Pharmacology, 2022, 30, 24.	0.9	3
5	Characterization of Clofazimine as a Potential Substrate of Drug Transporter. Antimicrobial Agents and Chemotherapy, 2022, 66, e0215821.	3.2	2
6	Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation. Healthcare Informatics Research, 2022, 28, 176-180.	1.9	2
7	Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management. Pharmaceutics, 2022, 14, 990.	4.5	8
8	Identification and functional study of genetic polymorphisms in cyclic nucleotide phosphodiesterase 3A (PDE3A). Annals of Human Genetics, 2021, 85, 80-91.	0.8	3
9	Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. Journal of Clinical Pharmacology, 2021, 61, 913-922.	2.0	10
10	Associations between HLA-A, -B, and -C alleles and iodinated contrast mediaâ€"induced hypersensitivity in Koreans. Translational and Clinical Pharmacology, 2021, 29, 107.	0.9	1
11	Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. Journal of Clinical Pharmacology, 2021, 61, 1567-1578.	2.0	14
12	Paraâ€aminosalicylic acid significantly reduced tenofovir exposure in human subjects; mismatched findings from in vitro to in vivo translational research. British Journal of Clinical Pharmacology, 2021, , .	2.4	3
13	A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction. Tuberculosis, 2021, 131, 102138.	1.9	10
14	Identification and functional characterization of CYP4V2 genetic variants exhibiting decreased activity of lauric acid metabolism. Annals of Human Genetics, 2020, 84, 400-411.	0.8	4
15	Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 153, 102055.	2.2	4
16	Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy. Translational and Clinical Pharmacology, 2020, 28, 34.	0.9	14
17	Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: A report of five cases with lymphocyte activation test. Translational and Clinical Pharmacology, 2019, 27, 64.	0.9	5
18	NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population. Pharmacogenomics, 2019, 20, 1303-1311.	1.3	15

#	Article	IF	Citations
19	Physiologically Based Pharmacokinetic Modeling Approach to Predict Drugâ€Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. Journal of Clinical Pharmacology, 2019, 59, 880-889.	2.0	7
20	Rifampin Induces Expression of P-glycoprotein on the THP1 Cellâ€“Derived Macrophages, Causing Decrease Intramacrophage Concentration of Prothionamide. Journal of Pharmaceutical Sciences, 2019, 108, 3106-3111.	3.3	4
21	Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. Clinical Therapeutics, 2019, 41, 961-971.	2.5	5
22	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. BioDrugs, 2019, 33, 173-181.	4.6	14
23	Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. Drug Metabolism and Pharmacokinetics, 2019, 34, 201-208.	2.2	8
24	Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. BioMed Research International, 2019, 2019, 1-6.	1.9	5
25	Effect of rifampin on enantioselective disposition and antiâ€hypertensive effect of benidipine. British Journal of Clinical Pharmacology, 2019, 85, 737-745.	2.4	3
26	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. AAPS Journal, 2019, 21, 17.	4.4	29
27	Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 131, 6-13.	2.2	20
28	Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters In Vitro. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
29	Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavinâ€Containing Monooxygenase 3 Maturational Changes Over Time. Journal of Clinical Pharmacology, 2018, 58, 1347-1360.	2.0	6
30	THE EFFECTS OF CANDIDATE GENE IN PKPD PATHWAY ON ANTIPSYCHOTICS-INDUCED AMENORRHEA IN FEMALE SCHIZOPHRENIA PATIENTS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-24.	0.0	0
31	Effects of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-15.	0.0	0
32	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cellular Signalling, 2017, 31, 124-134.	3.6	27
33	Evaluation of para -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
34	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. Applied Health Economics and Health Policy, 2017, 15, 657-667.	2.1	17
35	Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. Journal of Pharmaceutical Sciences, 2017, 106, 2368-2379.	3.3	157
36	Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis. Archives of Biochemistry and Biophysics, 2017, 620, 43-51.	3.0	12

#	Article	IF	Citations
37	Expression of CYP4V2 in human THP1 macrophages and its transcriptional regulation by peroxisome proliferator-activated receptor gamma. Toxicology and Applied Pharmacology, 2017, 330, 100-106.	2.8	16
38	Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Drug Design, Development and Therapy, 2017, Volume 11, 3543-3550.	4.3	7
39	Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. Journal of Clinical Pharmacology, 2016, 56, 576-580.	2.0	16
40	The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. Journal of Clinical Pharmacology, 2016, 56, 1372-1377.	2.0	1
41	The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. British Journal of Clinical Pharmacology, 2016, 81, 301-312.	2.4	21
42	Population Pharmacokineticâ€“Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. Clinical Therapeutics, 2016, 38, 2610-2621.	2.5	8
43	Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. Antimicrobial Agents and Chemotherapy, 2016, 60, 6558-6567.	3.2	26
44	Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 339-344.	1.6	14
45	Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake. Antimicrobial Agents and Chemotherapy, 2016, 60, 3096-3105.	3.2	21
46	Characterization of urinary metabolites as biomarkers of colistin-induced nephrotoxicity in rats by a liquid chromatography/mass spectrometry-based metabolomics approach. Toxicology Letters, 2016, 248, 52-60.	0.8	12
47	Contribution of GABRG2 Polymorphisms to Risk of Epilepsy and Febrile Seizure: a Multicenter Cohort Study and Meta-analysis. Molecular Neurobiology, 2016, 53, 5457-5467.	4.0	25
48	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metabolism and Pharmacokinetics, 2016, 31, 107-116.	2.2	14
49	Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. Yonsei Medical Journal, 2015, 56, 961.	2.2	19
50	Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. Xenobiotica, 2015, 45, 10-18.	1.1	26
51	Analysis of genetic polymorphism and biochemical characterization of a functionally decreased variant in prostacyclin synthase gene (CYP8A1) in humans. Archives of Biochemistry and Biophysics, 2015, 569, 10-18.	3.0	19
52	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2015, 75, 173-182.	2.3	37
53	Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. Toxicology and Applied Pharmacology, 2015, 288, 213-222.	2.8	16
54	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp90Î² as a Novel Mechanism of Rifampin-induced MDR1 Expression. Journal of Biological Chemistry, 2015, 290, 17029-17040.	3.4	26

#	Article	IF	Citations
55	Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatographyâ€“electrospray ionizationâ€“tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 9-16.	2.8	85
56	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. Translational and Clinical Pharmacology, 2014, 22, 70.	0.9	8
57	EnantioselectiveN-Demethylation and Hydroxylation of Sibutramine in Human Liver Microsomes and Recombinant Cytochrome P-450 Isoforms. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2014, 77, 1419-1430.	2.3	4
58	In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatographyâ€“Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2014, 42, 1803-1810.	3.3	39
59	Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel. International Journal of Molecular Sciences, 2014, 15, 7699-7710.	4.1	5
60	Resolution of a clinical AmpliChip CYP450 Testâ„¢ no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics, 2014, 15, 1175-1184.	1.3	11
61	The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy <scp>K</scp>orean subjects. British Journal of Clinical Pharmacology, 2014, 77, 821-830.	2.4	17
62	The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. Journal of Clinical Pharmacology, 2014, 54, 850-857.	2.0	9
63	Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine. Drug Metabolism and Disposition, 2014, 42, 141-152.	3.3	15
64	Genetic Variations in UDP-glucuronosyltransferase 2B15 in a Korean Population. Drug Metabolism and Pharmacokinetics, 2014, 29, 105-109.	2.2	1
65	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application. , 2014, , 345-370.		1
66	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (â‰¥80Â% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatology International, 2013, 7, 1000-1009.	4.2	2
67	Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. Xenobiotica, 2013, 43, 211-218.	1.1	5
68	CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina. Circulation: Cardiovascular Genetics, 2013, 6, 514-521.	5.1	39
69	Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. British Journal of Clinical Pharmacology, 2013, 75, 244-253.	2.4	23
70	Reply to: Letter to the Editor â€œImpact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitorsâ€• Journal of Clinical Pharmacology, 2013, 53, 360-360.	2.0	0
71	The Tyrosine Kinase Inhibitor Nilotinib Selectively Inhibits CYP2C8 Activities in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics, 2013, 28, 462-467.	2.2	10
72	Single Nucleotide Polymorphisms in SULT1A1 and SULT1A2 in a Korean Population. Drug Metabolism and Pharmacokinetics, 2013, 28, 372-377.	2.2	4

#	Article	IF	Citations
73	Effect of HNF4Î± genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. Pharmacogenetics and Genomics, 2013, 23, 175-179.	1.5	6
74	Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent. PLoS ONE, 2013, 8, e64114.	2.5	23
75	Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica, 2012, 42, 278-284.	1.1	27
76	LCâ€“MS/MS for the simultaneous analysis of arachidonic acid and 32 related metabolites in human plasma: Basal plasma concentrations and aspirin-induced changes of eicosanoids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 911, 113-121.	2.3	77
77	Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole. Journal of Clinical Pharmacology, 2012, 52, 976-984.	2.0	33
78	Rapid genotyping of the genetic variants of organic anion transporter 1 (OAT1), R50H, R23W, R454Q, and 505C>T, by pyrosequencing method. Journal of Pharmaceutical Investigation, 2012, 42, 71-76.	5.3	1
79	High-sensitivity liquid chromatographyâ€“tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 56-64.	2.3	39
80	The Development of Automated Bed-allocation Expert System in Clinical Research Ward. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 51.	0.1	0
81	Genetic polymorphisms in Na⁺-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica, 2011, 41, 501-510.	1.1	89
82	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenetics and Genomics, 2011, 21, 820-828.	1.5	15
83	Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 771-777.	2.8	70
84	Differential effect of genetic variants of Na+-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica, 2011, 41, 24-34.	1.1	74
85	Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo. Drug Metabolism and Disposition, 2011, 39, 711-716.	3.3	21
86	In vitrometabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. Xenobiotica, 2011, 41, 445-455.	1.1	7
87	Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population. Molecular Biology Reports, 2010, 37, 213-217.	2.3	11
88	Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4â€hydroxybupropion, in healthy subjects. British Journal of Clinical Pharmacology, 2010, 70, 126-131.	2.4	11
89	A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients. British Journal of Clinical Pharmacology, 2010, 70, 213-221.	2.4	18
90	Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants. Journal of Clinical Pharmacology, 2010, 50, 195-204.	2.0	13

#	Article	IF	Citations
91	Genetic Variations in UDP-glucuronosyltransferase 2B7 Gene (UGT2B7) in a Korean Population. Drug Metabolism and Pharmacokinetics, 2010, 25, 398-402.	2.2	15
92	Murrayafoline A attenuates the Wnt/Î²-catenin pathway by promoting the degradation of intracellular Î²-catenin proteins. Biochemical and Biophysical Research Communications, 2010, 391, 915-920.	2.1	35
93	Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clinica Chimica Acta, 2010, 411, 2043-2048.	1.1	18
94	Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. Journal of Human Genetics, 2010, 55, 189-193.	2.3	19
95	Identification of NewCYP2C19Variants Exhibiting Decreased Enzyme Activity in the Metabolism ofS-Mephenytoin and Omeprazole. Drug Metabolism and Disposition, 2009, 37, 2262-2269.	3.3	38
96	Stimulation of protein kinase Câ€Î± suppresses colon cancer cell proliferation by downâ€regulation of Î²â€catenin. Journal of Cellular and Molecular Medicine, 2009, 13, 2171-2180.	3.6	33
97	Isoreserpine promotes Î²-catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells. Biochemical and Biophysical Research Communications, 2009, 387, 444-449.	2.1	22
98	Discovery of Novel Functional Variants and Extensive Evaluation ofCYP2D6Genetic Polymorphisms in Koreans. Drug Metabolism and Disposition, 2009, 37, 1464-1470.	3.3	64
99	Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics and Genomics, 2009, 19, 103-112.	1.5	48
100	Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin. Pharmaceutical Research, 2008, 25, 1807-1814.	3.5	57
101	Genetic polymorphism of hepatocyte nuclear factor-4Î± influences human cytochrome P450 2D6 activity. Hepatology, 2008, 48, 635-645.	7.3	25
102	Simultaneous determination of udenafil and its active metabolite, DAâ€8164, in human plasma and urine using ultraâ€performance liquid chromatographyâ€“tandem mass spectrometry: application to a pharmacokinetic study. Biomedical Chromatography, 2008, 22, 939-946.	1.7	13
103	Determination of two HMGâ€CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatographyâ€“tandem mass spectrometry for pharmaceutical study. Biomedical Chromatography, 2008, 22, 131-135.	1.7	31
104	Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatographyâ€“tandem mass spectrometry: application to pharmacokinetic study of Astrix^{Â®} in Korean healthy volunteers. Biomedical Chromatography, 2008, 22, 590-595.	1.7	49
105	The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chemico-Biological Interactions, 2008, 174, 141-146.	4.0	31
106	Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. Clinica Chimica Acta, 2008, 388, 68-72.	1.1	23
107	Duplex pyrosequencing of the TPMTâŽ3C and TPMTâŽ6 alleles in Korean and Vietnamese populations. Clinica Chimica Acta, 2008, 398, 82-85.	1.1	19
108	The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. Drug Metabolism and Disposition, 2008, 36, 986-990.	3.3	53

#	Article	IF	Citations
109	Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes. Drug Metabolism and Disposition, 2008, 36, 1679-1688.	3.3	40
110	Identification and Characterization of Potent CYP2B6 Inhibitors in Woohwangcheongsimwon Suspension, an Herbal Preparation Used in the Treatment and Prevention of Apoplexy in Korea and China. Drug Metabolism and Disposition, 2008, 36, 1010-1015.	3.3	30
111	Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population. Drug Metabolism and Disposition, 2007, 35, 667-675.	3.3	93
112	The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals. Drug Metabolism and Disposition, 2007, 35, 2095-2101.	3.3	26
113	Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population. Drug Metabolism and Disposition, 2007, 35, 623-632.	3.3	55
114	Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations. Therapeutic Drug Monitoring, 2007, 29, 455-459.	2.0	38
115	Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2007, 35, 1518-1524.	3.3	30
116	Development of the â€œInje Cocktailâ€•for High-throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo. Clinical Pharmacology and Therapeutics, 2007, 82, 531-540.	4.7	121
117	The effect of ABCG2ÂV12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. British Journal of Clinical Pharmacology, 2007, 64, 645-654.	2.4	51
118	Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms. Archives of Pharmacal Research, 2007, 30, 469-474.	6.3	2
119	Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. Toxicology Letters, 2006, 166, 105-114.	0.8	10
120	In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid Communications in Mass Spectrometry, 2006, 20, 837-843.	1.5	7
121	Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical Pharmacology and Therapeutics, 2006, 79, 590-599.	4.7	52
122	Hexachlorophene Inhibits Wnt/Î²-Catenin Pathway by Promoting Siah-Mediated Î²-Catenin Degradation. Molecular Pharmacology, 2006, 70, 960-966.	2.3	112
123	Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A. Drug Metabolism and Disposition, 2006, 34, 1793-1797.	3.3	75
124	Protein-kinase-C-mediated Î²-catenin phosphorylation negatively regulates the Wnt/Î²-catenin pathway. Journal of Cell Science, 2006, 119, 4702-4709.	2.0	95
125	Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenetics and Genomics, 2005, 15, 105-113.	1.5	50
126	MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnamese Populations. Therapeutic Drug Monitoring, 2005, 27, 531-535.	2.0	36

#	Article	IF	Citations
127	Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population. Therapeutic Drug Monitoring, 2005, 27, 208-210.	2.0	32
128	Analysis of benidipine enantiomers in human plasma by liquid chromatographyâ€“mass spectrometry using a macrocyclic antibiotic (Vancomycin) chiral stationary phase column. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 75-81.	2.3	19
129	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism. Clinical Pharmacology and Therapeutics, 2005, 78, 191-201.	4.7	68
130	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. British Journal of Clinical Pharmacology, 2005, 59, 552-563.	2.4	14
131	In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes. Archives of Pharmacal Research, 2005, 28, 1287-1292.	6.3	6
132	High-throughput screening of inhibitory potential of nine cytochrome P450 enzymesin vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 2651-2658.	1.5	148
133	Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazolein vitro. Xenobiotica, 2005, 35, 27-38.	1.1	24
134	Diclofenac attenuates Wnt/Î²-catenin signaling in colon cancer cells by activation of NF-ÎºB. FEBS Letters, 2005, 579, 4213-4218.	2.8	55
135	Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. British Journal of Clinical Pharmacology, 2004, 58, 397-402.	2.4	42
136	Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column. Chromatographia, 2004, 60, 639-643.	1.3	12
137	Determination of benidipine in human plasma using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 311-314.	2.3	20
138	Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 75-80.	2.3	31
139	Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2004, 75, 157-162.	4.7	82
140	Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states*1. Clinical Pharmacology and Therapeutics, 2004, 76, 104-112.	4.7	98
141	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica, 2004, 34, 429-438.	1.1	18
142	STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES. Drug Metabolism and Disposition, 2003, 31, 1227-1234.	3.3	64
143	Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction between TCAs and Phenytoin. Drug Metabolism and Disposition, 2002, 30, 1102-1107.	3.3	67
144	Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics and Genomics, 2002, 12, 111-119.	5.7	86

#	Article	IF	Citations
145	Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clinical Pharmacokinetics, 2002, 41, 913-958.	3.5	771
146	Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19*. Clinical Pharmacology and Therapeutics, 2002, 72, 90-99.	4.7	68
147	Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. British Journal of Clinical Pharmacology, 2001, 51, 277-280.	2.4	107
148	Assessment of Efficacy and Safety of Haloxazolam in Psychiatric Patients with Insomnia. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1995, 3, 36.	0.1	0
149	Bioequivalence of Generic Nortriptyline Tablet. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1993, 1, 3.	0.1	0